Literature DB >> 25086499

Akt and p53R2, partners that dictate the progression and invasiveness of cancer.

Bahman Yousefi1, Nasser Samadi2, Yasin Ahmadi3.   

Abstract

The serine/threonine kinase or the so-called "Akt" is a key regulatory molecule of signaling pathway that regulates various cellular processes. Many intracellular proteins are involved in the activation or inhibition of Akt signaling and the hyperactivation of Akt signaling pathway is found to be frequently involved in various types of human cancers. Furthermore, while p53R2, a p53-inducible peptide involved in the synthesis of dNTPs normally works toward suppression of cancer through elimination of reactive oxygen species (ROS), inhibition of MAPK/ERK pathway and providing dNTPs for DNA repair, the overexpression of p53R2 is reported to be associated with cancer progression and resistance to therapy. In this review article, we will discuss the situation in which cancer cells with hyperactive PI3K/Akt signaling can recruit p53R2 in favor of cancer progression and resistance to therapy. In the hyperactive state of PI3K/Akt signaling (which happens in the absence of deactivation or excess of activation), p53R2 can be used by cancer cells to promote proliferation. Therefore, the hyperactivity of PI3K/Akt pathway and elevated levels of p53R2 can give rise to highly invasive cancers.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akt; Cancer progression; Cell cycle; P53R2; Ribonucleotide reductase

Mesh:

Substances:

Year:  2014        PMID: 25086499     DOI: 10.1016/j.dnarep.2014.07.001

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  9 in total

1.  p53R2 is oncogenic in human cervical cancer.

Authors:  Huang Bo; Cai Weiyang; Yanjie Zhang
Journal:  Cell Cycle       Date:  2017-06-28       Impact factor: 4.534

2.  Chronic type-I diabetes could not impede the anti-inflammatory and anti-apoptotic effects of combined postconditioning with ischemia and cyclosporine A in myocardial reperfusion injury.

Authors:  Reza Badalzadeh; Ako Azimi; Alireza Alihemmati; Bahman Yousefi
Journal:  J Physiol Biochem       Date:  2016-10-22       Impact factor: 4.158

3.  MTBSTFA derivatization-LC-MS/MS approach for the quantitative analysis of endogenous nucleotides in human colorectal carcinoma cells.

Authors:  Huixia Zhang; Yan Li; Zheng Li; Christopher Wai-Kei Lam; Peng Zhu; Caiyun Wang; Hua Zhou; Wei Zhang
Journal:  J Pharm Anal       Date:  2021-01-22

Review 4.  Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews.

Authors:  Xīn Gào; Ben Schöttker
Journal:  Oncotarget       Date:  2017-04-16

5.  miR-205 Reverses MDR-1 Mediated Doxorubicin Resistance via PTEN in Human Liver Cancer HepG2 Cells.

Authors:  Mei Li; Z Hubin Li; Juanrong Song; Xu Li; Pengtao Zhai; Xudong Mu; Fakai Qiu; Le Yao
Journal:  Cell J       Date:  2022-03       Impact factor: 3.128

Review 6.  Regulation of DNA duplication by the mTOR signaling pathway.

Authors:  Zhengfu He; Peter J Houghton; Terence M Williams; Changxian Shen
Journal:  Cell Cycle       Date:  2021-03-10       Impact factor: 4.534

7.  Cardioprotective Effect of Quercetin against Ischemia/Reperfusion Injury Is Mediated Through NO System and Mitochondrial K-ATP Channels.

Authors:  Ying Liu; Yi Song; Siyuan Li; Li Mo
Journal:  Cell J       Date:  2021-05-26       Impact factor: 2.479

8.  The Succinate Receptor GPR91 Is Involved in Pressure Overload-Induced Ventricular Hypertrophy.

Authors:  Lei Yang; Di Yu; Ran Mo; Jiru Zhang; Hu Hua; Liang Hu; Yu Feng; Song Wang; Wei-Yan Zhang; Ning Yin; Xu-Ming Mo
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

9.  5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer.

Authors:  Richard Daifuku; Zhenbo Hu; Yogen Saunthararajah
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.